Compare British American Tobacco PLC (BTI) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Cytokinetics Inc — how do they compare? British American Tobacco PLC trades at $57.01 (market cap $120.84B), while Cytokinetics Inc trades at $73.05 (market cap $10.52B). The key difference: British American Tobacco PLC is far larger — about 11.5× Cytokinetics Inc's market cap, and British American Tobacco PLC pays a 5.98% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| BTI | CYTK | |
|---|---|---|
Market Cap | $120.84B | $10.52B |
Sector | Consumer Staples | Technology |
52-Week High | $66.70 | $87.26 |
52-Week Low | $50.39 | $35.33 |
Enterprise Value | $164.79B | $10.62B |
Dividend Yield | 5.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
British American Tobacco (BTI) trades at $57.35, up 0.95% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 24.99% net income margin and 13.33% ROE, supported by $25.6B revenue. Recent restructuring including 5,500 job cuts aims to streamline operations while maintaining dividend payments of $0.83 per share. Cash flow trends show operational strength despite recent net cash outflow of -$1.1B in 2025.
BTI presents a mixed outlook with attractive valuation (P/E 14.21) and 66.7% analyst buy rating, but faces regulatory headwinds and declining combustible sales. The transition to next-generation products like Velo nicotine pouches shows promise, though execution risks remain. The stock offers income appeal with consistent dividends but requires monitoring of debt levels and market share trends in non-combustible segments.
Cytokinetics (CYTK) trades at $75.64, down 1.06% with a bearish technical signal. The company shows strong commercial momentum with Myqorzo gaining traction internationally, but faces significant financial challenges including negative gross margin of -372.55% and net income margin of -1,321.12%. Recent Q2 2026 earnings beat revenue estimates despite posting losses, while regulatory approvals in the UK expand market access.
Investment outlook balances promising drug pipeline against substantial financial losses. Analyst consensus remains overwhelmingly bullish with 97% buy ratings and $111.14 price target, representing 47% upside potential. Key risks include high cash burn, competitive pressures, and the need for continued financing to support operations and drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
